Skip to main content
Premium Trial:

Request an Annual Quote

Michael Savage, Arnold Levine, Gregory Abbott, Jon Saxe, Randy Scott.

Premium

Genomica of Boulder, Colo., has appointed Michael Savage to its board of directors. Savage was CEO of Molecular Simulations from 1991 until the company was acquired by Pharmacopeia in 1998 and is currently principal of Savage Consulting.

Savage will fill the board seat being vacated by Arnold Levine, president of Rockefeller University and a scientific trustee of Cold Spring Harbor Laboratory, who is joining the company’s scientific advisory board.

Gregory Abbott and Jon Saxe have been appointed to the board of directors of diaDexus of Santa Clara, Calif.

Abbott is the managing partner of the Seattle office of law firm Cooley Godward and previously served as CEO at Synergen, acquired by Amgen; Darwin Molecular, acquired by Chiroscience; and AlphaGene.

Saxe currently sits on the boards of several companies and served as president of Protein Design Labs and Saxe Associates and president and CEO of Synergen. Saxe takes the place of Randy Scott, who stepped down to focus on his new company, Genomic Health.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.